AIM: To evaluate the psychometrics of the EORTC QLQ-PR25, a questionnaire assessing the health-related quality of life of prostate cancer patients. METHODS: The QLQ-PR25 and the QLQ-C30 were administered to 642 prostate cancer patients from 13 countries treated with curative or palliative intent. The QLQ-PR25 assesses urinary, bowel and sexual symptoms and functioning, and the side-effects of hormonal treatment. RESULTS: Five hundred and nine patients were available for the final analysis. Multitrait scaling analyses confirmed the hypothesised scale structure of the QLQ-PR25. Internal consistency reliability was good (coefficient alpha=0.70-0.86) for the urinary symptoms and sexual function scales, but lower for the bowel function and side-effects of hormonal treatment scales (alpha<0.70). The module discriminated clearly between clinically distinct patient subgroups, and was responsive to changes in health status over time. CONCLUSION: In general, the QLQ-PR25 demonstrates acceptable psychometric properties and clinical validity. Some caution should be used in interpreting the bowel function and side-effects of hormonal therapy scales; results can be reported at the individual item and scale level.
AIM: To evaluate the psychometrics of the EORTC QLQ-PR25, a questionnaire assessing the health-related quality of life of prostate cancerpatients. METHODS: The QLQ-PR25 and the QLQ-C30 were administered to 642 prostate cancerpatients from 13 countries treated with curative or palliative intent. The QLQ-PR25 assesses urinary, bowel and sexual symptoms and functioning, and the side-effects of hormonal treatment. RESULTS: Five hundred and nine patients were available for the final analysis. Multitrait scaling analyses confirmed the hypothesised scale structure of the QLQ-PR25. Internal consistency reliability was good (coefficient alpha=0.70-0.86) for the urinary symptoms and sexual function scales, but lower for the bowel function and side-effects of hormonal treatment scales (alpha<0.70). The module discriminated clearly between clinically distinct patient subgroups, and was responsive to changes in health status over time. CONCLUSION: In general, the QLQ-PR25 demonstrates acceptable psychometric properties and clinical validity. Some caution should be used in interpreting the bowel function and side-effects of hormonal therapy scales; results can be reported at the individual item and scale level.
Authors: Stefan Holmstrom; Shevani Naidoo; James Turnbull; Emily Hawryluk; Jean Paty; Robert Morlock Journal: Patient Date: 2019-02 Impact factor: 3.883
Authors: Desiree Jones; Fengmin Zhao; Michael J Fisch; Lynne I Wagner; Linda J Patrick-Miller; Charles S Cleeland; Tito R Mendoza Journal: Clin Genitourin Cancer Date: 2013-10-12 Impact factor: 2.872
Authors: Jens Klein; Daniel Lüdecke; Kerstin Hofreuter-Gätgens; Margit Fisch; Markus Graefen; Olaf von dem Knesebeck Journal: Qual Life Res Date: 2017-04-25 Impact factor: 4.147
Authors: Johannes Huber; Tanja Muck; Philipp Maatz; Bastian Keck; Paul Enders; Imad Maatouk; Andreas Ihrig Journal: J Cancer Surviv Date: 2017-08-31 Impact factor: 4.442
Authors: J I Arraras; E Villafranca; F Arias de la Vega; P Romero; M Rico; M Vila; G Asín; V Chicata; M A Domínguez; N Lainez; A Manterola; E Martínez; M Martínez Journal: Clin Transl Oncol Date: 2009-03 Impact factor: 3.405